Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma. Issue 4 (April 2023)

• Record Type: Journal Article
• Authors: Nie, Jiani; Li, Lianhe; Tan, Fuxian; Wang, Hongmei; Wang, Hongmin; Zou, Liangyu; Wen, Zhenlei
• Is Part Of: Journal of international medical research. Volume 51:Issue 4(2023)
• Publication Date: 2023-04
• Subjects: Laryngeal squamous cell carcinoma -- induction chemotherapy -- TPF -- chemosensitivity -- CADM1 -- biomarker; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/03000605231168017
• Languages: English
• ISSNs: 0300-0605

Abstract

Objectives: To explore the relationship between CADM1 expression and sensitivity to TPF-induced chemotherapy in laryngeal squamous cell carcinoma (LSCC) patients, then investigate its potential mechanisms. Methods: Differential CADM1 expression was examined in chemotherapy-sensitive and chemotherapy-insensitive LSCC patient samples after TPF-induced chemotherapy using microarray analysis. Receiver operating characteristic (ROC) curve analysis and bioinformatics approaches were used to investigate the diagnostic value of CADM1. Small interfering RNAs (siRNAs) were used to knock down CADM1 expression in an LSCC cell line. Differential CADM1 expression was compared by qRT-PCR assays in 35 LSCC patients treated with chemotherapy, including 20 chemotherapy-sensitive and 15 chemotherapy-insensitive patients. Results: Public database and primary patient data both suggest that CADM1 mRNA is expressed at lower levels in chemotherapy-insensitive LSCC samples, suggesting its potential usefulness as a biomarker. Knockdown of CADM1 with siRNAs led to decreased sensitivity of LSCC cells to TPF chemotherapy. Conclusions: Upregulation of CADM1 expression can alter the sensitivity of LSCC tumors to TPF induction chemotherapy. CADM1 is a possible molecular marker and therapeutic target for induction chemotherapy in LSCC patients.